Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.

Show other versions (1)

Malaria transmission is in decline in some parts of Africa, partly due to the scaling up of control measures. If the goal of elimination is to be achieved, additional control measures including an effective and durable vaccine will be required. Studies utilising the prime-boost approach to deliver v...

Bibliografske podrobnosti
Main Authors:	Mensah, V, Gueye, A, Ndiaye, M, Edwards, N, Wright, D, Anagnostou, N, Syll, M, Ndaw, A, Abiola, A, Bliss, C, Gomis, J, Petersen, I, Ogwang, C, Dieye, T, Viebig, N, Lawrie, A, Roberts, R, Nicosia, A, Faye, B, Gaye, O, Leroy, O, Imoukhuede, E, Ewer, K, Bejon, P, Hill, A, Cisse, B, MVVC Group
Format:	Journal article
Jezik:	English
Izdano:	Public Library of Science 2016

Podobne knjige/članki

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
od: Victorine A Mensah, et al.
Izdano: (2016-01-01)

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants
od: Bliss, C, et al.
Izdano: (2016)

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children
od: Tiono, AB, et al.
Izdano: (2018)

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
od: Ogwang, C, et al.
Izdano: (2013)

A Phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS
od: De Barra, E, et al.
Izdano: (2014)

Safety and immunogenicity of the heterologous prime-boost ebolavirus vaccine regimen CHAD3-EBO Z and MVA-BN (R) FILO in healthy UK adults
od: Rampling, T, et al.
Izdano: (2015)

Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals.
od: Hodgson, S, et al.
Izdano: (2014)

Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.
od: Kimani, D, et al.
Izdano: (2014)

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children.
od: Alfred B Tiono, et al.
Izdano: (2018-01-01)

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
od: Caroline Ogwang, et al.
Izdano: (2013-01-01)

Safety and high level efficacy of the combination malaria vaccine regimen of RTS,S/AS01B with ChAd-MVA vectored vaccines expressing ME-TRAP
od: Rampling, T, et al.
Izdano: (2016)

Evaluation of the efficacy of chad63-mva vectored vaccines expressing circumsporozoite protein and me-trap against controlled human malaria infection in malaria-naive individuals
od: Hodgson, SH, et al.
Izdano: (2014)

A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.
od: Eoghan de Barra, et al.
Izdano: (2014-01-01)

Phase Ia clinical evaluation of the plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors
od: Sheehy, S, et al.
Izdano: (2011)

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.
od: Sheehy, S, et al.
Izdano: (2011)

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
od: Sheehy, S, et al.
Izdano: (2012)

Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.
od: Elias, S, et al.
Izdano: (2014)

ChAd63-MVA-vectored blood-stage Malaria vaccines targeting MSP1 and AMA1: Assessment of efficacy against mosquito bite challenge in humans
od: Sheehy, S, et al.
Izdano: (2012)

ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.
od: Sheehy, S, et al.
Izdano: (2012)

Safety and Efficacy of Novel Malaria Vaccine Regimens of RTS,S/AS01B alone, or with Concomitant ChAd63-MVA Vectored Vaccines Expressing ME-TRAP
od: Rampling, T, et al.
Izdano: (2018)

Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure
od: Biswas, S, et al.
Izdano: (2014)

Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso
od: Richard Morter, et al.
Izdano: (2022-12-01)

Safety and immunogenicity of the novel plasmodium falciparum blood-stage vaccine chad63-mva rh5 in a phase ia clinical trial
od: Payne, R, et al.
Izdano: (2017)

Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure.
od: Sumi Biswas, et al.
Izdano: (2014-01-01)

Durability of immune responses induced by three leading candidate ebola vaccine regimes; rVSV ZEBOV, ChAd3 EBO Z-MVA BN-Filo and AdHu26.ZEBOV-MVA BN Filo
od: Ewer, K, et al.
Izdano: (2018)

A monovalent chimpanzee adenovirus ebola vaccine boosted with MVA
od: Ewer (nee Russell), K, et al.
Izdano: (2016)

Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial
od: Hans de Graaf, et al.
Izdano: (2021-07-01)

Safety and immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I first-in-human trial
od: de Graaf, H, et al.
Izdano: (2021)

Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso
od: Morter, R, et al.
Izdano: (2022)

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
od: Ewer, K, et al.
Izdano: (2013)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects
od: Dieye, T, et al.
Izdano: (2013)

Viral vector malaria vaccines induce high-level T cell and antibody responses in West African children and infants
od: Bliss, C, et al.
Izdano: (2016)

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.
od: O'Hara, G, et al.
Izdano: (2012)

HETEROLOGOUS PRIME-BOOST VACCINATION WITH ADCH63 AND MVA EXPRESSING MSP1 CAN INDUCE PROTECTIVE EFFICACY AGAINST SPOROZOITE CHALLENGE IN VOLUNTEERS
od: Sheehy, S, et al.
Izdano: (2010)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
od: Rowland, R, et al.
Izdano: (2012)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.
od: Tandakha N Dieye, et al.
Izdano: (2013-01-01)

Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects.
od: Tandakha N. Dieye, et al.
Izdano: (2013-01-01)

Safety and immunogenicity of malaria vectored vaccines given with routine EPI vaccines in Gambian infants and neonates: a randomized controlled trial
od: Mensah, V, et al.
Izdano: (2017)

Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial
od: Victorine A. Mensah, et al.
Izdano: (2017-11-01)

O'nyong-nyong Virus, Chad
od: Maël Bessaud, et al.
Izdano: (2006-08-01)